Skip to main content
Official Website of Stem Cell Mexico – Since 2002
Stem Cell Therapy Mexico

How is stem cell treatment for congestive heart failure done?

At Stem Cell Mexico, stem cell treatment for congestive heart failure (CHF) is a structured, minimally invasive process built around cardiac safety.

Free Consultation
Heart location on a neutral human figure

It begins with a review of your echocardiogram, ECG, laboratory results and cardiology reports, continues with a consultation with the doctor, a written plan and an in-person evaluation, and centers on a slow, monitored intravenous (IV) infusion of allogeneic mesenchymal stem cells (MSCs) from Wharton's jelly of the umbilical cord, with careful control of fluid volume. Treatment is followed by observation, usually overnight, discharge with written instructions and follow-up with repeat testing, ideally coordinated with your cardiologist. No autologous cells or other cell sources are used. Every plan is reviewed by the medical team with attention to your heart condition. The treatment complements, but never replaces, guideline-based heart failure care.

This guide walks through each step and explains the precautions specific to heart failure.

Why heart failure requires special precautions

People with heart failure are sensitive to changes in fluid volume, blood pressure, heart rhythm and electrolytes. Travel, fasting, changes in routine and an IV infusion can all affect this balance. For this reason, the process focuses on:

  • Confirming stability before treatment.
  • Keeping infusion volume low and monitoring fluid status.
  • Maintaining your cardiac medications on schedule.
  • Watching closely for any sign of decompensation.

A typical itinerary

  • Day 1: pickup in the San Diego area, border crossing with a driver, laboratory tests, ECG and in-person consultation with the doctor.
  • Day 2: IV infusion in the morning, followed by observation for the rest of the day and, usually, overnight.
  • Day 3: medical review of vital signs, weight and symptoms, discharge instructions and return to San Diego.

The exact itinerary is confirmed in your written plan. Patients who need extra rest or monitoring may stay longer.

Step 1: Records review

You send:

  • A recent echocardiogram (ideally within the past six months), including ejection fraction.
  • A recent ECG, and Holter monitoring results if available.
  • Laboratory results: kidney function, electrolytes (sodium, potassium), complete blood count and NT-proBNP or BNP when available.
  • Cardiology notes, including diagnosis, cause of heart failure, NYHA class and recent hospitalizations.
  • Information about implanted devices, such as a pacemaker, defibrillator (ICD) or cardiac resynchronization device.
  • A complete medication list, including anticoagulants and diuretics.

Step 2: Consultation with the doctor

A complimentary phone or video consultation allows the doctor to review your heart condition, discuss your goals and explain what regenerative treatment can and cannot do. The doctor will confirm whether your heart failure is stable and whether your medication plan appears optimized, and may recommend that you discuss adjustments with your cardiologist before treatment. Goals are defined in measurable terms, such as exercise tolerance, NYHA class, ejection fraction or quality of life.

Step 3: Written plan and preparation

If treatment is considered appropriate, you receive a written plan with the cell dose, route, itinerary, inclusions and costs. Typical preparation instructions include:

  • Continue all cardiac medications on schedule, including beta blockers, ARNI or ACE inhibitors, mineralocorticoid receptor antagonists, SGLT2 inhibitors and diuretics, unless the doctor indicates otherwise.
  • Anticoagulants are never stopped without medical guidance.
  • Pausing anti-inflammatory painkillers (which can worsen heart failure), alcohol and certain supplements, as the doctor indicates.
  • Weigh yourself daily in the week before travel and bring a record.
  • Follow fasting instructions adapted to your medications.
  • Bring your device identification card if you have a pacemaker or ICD.

Step 4: Arrival and evaluation

On arrival, you have blood tests, including kidney function and electrolytes, an ECG and an in-person evaluation. The doctor checks your weight, blood pressure, heart rate, oxygen level, lung sounds and leg swelling. If there are signs of decompensation, such as fluid overload, new arrhythmia, low oxygen or abnormal potassium, treatment is postponed.

Step 5: The IV infusion

The cells

Allogeneic MSCs from Wharton's jelly of donated umbilical cords, obtained after healthy, full-term births with informed consent and donor screening. They are produced in a COFEPRIS-licensed laboratory under Good Manufacturing Practice standards, with quality and safety testing before release.

The procedure

  1. A small IV catheter is placed in your arm.
  2. Baseline blood pressure, heart rate, oxygen saturation and temperature are recorded, with continuous cardiac monitoring when indicated.
  3. The cells are infused slowly, usually over 30 to 60 minutes, in the lowest appropriate fluid volume.
  4. Vital signs are monitored throughout and after the infusion.

The IV route is the one used in the RIMECARD randomized trial of umbilical cord MSCs in heart failure, published in Circulation Research. After infusion, many cells are temporarily filtered by the lungs, and their effects are believed to occur through systemic anti-inflammatory and signaling mechanisms.

Other routes in research

Some trials, such as DREAM-HF, injected cells directly into the heart muscle through a catheter. That approach requires a cardiac catheterization laboratory and carries procedural risks, and it is used in specific research settings.

Step 6: Observation

You remain under nursing and medical supervision, usually overnight. The team monitors:

  • Blood pressure, heart rate and rhythm, and oxygen levels.
  • Fluid balance and breathing.
  • Temperature, since temporary fever is the most common reaction to IV MSCs.

Paracetamol (acetaminophen) is used if fever appears; anti-inflammatory painkillers are avoided.

Step 7: Discharge and recovery

Before discharge, the doctor reviews your vital signs, weight and symptoms, and gives written instructions:

  • Rest on the day of treatment and the following day, then resume light activity.
  • Continue all medications and your usual salt and fluid guidance.
  • Weigh yourself daily and record the results.
  • Possible mild fever, headache or fatigue for a day or two.
  • Seek urgent care for shortness of breath at rest, chest pain, rapid weight gain, fainting or a very fast or irregular heartbeat.

No treatment is free of risk, and these instructions help detect problems early.

Step 8: Follow-up and measurement

  • Follow-up calls at regular intervals.
  • Repeat echocardiogram, NT-proBNP and functional tests, such as a six-minute walk, at about 3, 6 and 12 months, ideally by your cardiologist.
  • Quality-of-life questionnaires compared with baseline.
  • Coordination with your cardiologist, who continues to manage your medications and devices.

If your symptoms or test results change significantly during follow-up, your cardiologist should guide any adjustment to your heart failure treatment.

Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.

How treatment fits with standard care

The European Society of Cardiology (ESC) guidelines base heart failure treatment on medications, devices and lifestyle measures proven to reduce deaths and hospitalizations. Cell therapy is not part of these guidelines and should be added to optimized care, never used to replace it. A Cochrane review and the DREAM-HF trial show that evidence for cell therapy remains mixed, which is why objective follow-up matters.

Traveling safely with heart failure

  • Bring enough medication for the whole trip plus a few extra days, in original containers, with a written list of doses.
  • Avoid salty restaurant and travel food as much as possible; ask the coordination team about meal options during your stay.
  • Stay mobile on long trips by standing and walking periodically to reduce the risk of blood clots, and wear compression stockings if your doctor recommends them.
  • Carry your cardiology summary and device card in your hand luggage.
  • Plan the timing of diuretics so you have access to restrooms during the drive and border crossing; discuss this with the doctor rather than skipping doses.
  • Travel with a companion when possible, especially if you have moderate to severe symptoms.

If you notice increasing shortness of breath, swelling or chest discomfort before the trip, tell the coordination team and your cardiologist. Postponing treatment until you are stable is always the safer choice.

Who may be a candidate

  • Stable chronic heart failure on optimized medical therapy for several months.
  • No recent heart attack, unstable angina or hospitalization for decompensation.
  • Controlled blood pressure, acceptable kidney function and normal potassium.
  • No active infection and no cancer within the past five years.
  • Continued follow-up with a cardiologist.

Questions to ask during your evaluation

  • How will my fluids and medications be managed during the stay?
  • Will I have continuous cardiac monitoring?
  • Which tests will measure change, and when?
  • What results are realistic for my type and stage of heart failure?
  • How will you communicate with my cardiologist?

Bottom line

Stem cell treatment for congestive heart failure at Stem Cell Mexico follows a cardiac-focused, step-by-step process: records review, consultation, preparation, evaluation, a slow, monitored IV infusion of Wharton's jelly MSCs, overnight observation and follow-up with repeat testing. It is a complement to proven heart failure care, with results that vary between individuals. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your heart condition, goals and medical history.

References

  1. European Society of Cardiology (ESC): 2021 Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal (opens in a new tab)
  2. Bartolucci J et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial). Circulation Research, 2017 (opens in a new tab)
  3. Perin EC et al. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure (DREAM-HF). Journal of the American College of Cardiology, 2023 (opens in a new tab)
  4. Cochrane: Fisher SA et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure, 2016 (opens in a new tab)
  5. Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)

Request your medical evaluation

A clearer path starts here.

Tell us a little about yourself. We’ll help you understand the next step.

Vania, patient coordinator at Stem Cell Mexico

Vania, our patient coordinator

Your questions. Your travel plans.
A real person to help.

Talk to Vania on WhatsApp (opens in a new tab)

What happens next?

  1. Your advisor contacts you.
  2. We explain the medical review.
  3. You explore your options.

Call +1 800 646 0290

Let’s begin with you.

Your inquiry starts a conversation. Treatment requires medical evaluation.

Vania · Patient Advisor

Start my free evaluation
Free Consultation